PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) 05.04.2004 01.04.2005 PCT/US2005/011372 International Patent Classification (IPC) or both national classification and IPC INV. A61K31/439 A61P31/18 A61P37/00 Applicant SAMARITAN PHARMACEUTICALS, INC. This opinion contains indications relating to the following items: Box No. I Basis of the opinion ☐ Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III ☐ Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited Certain defects in the international application ☐ Box No. VII ☐ Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized Officer Name and mailing address of the ISA: Date of completion of this opinion

see form

PCT/ISA/210

Albayrak, Timur

Telephone No. +49 89 2399-7549



European Patent Office

Fax: +49 89 2399 - 4465

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

D-80298 Munich

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2005/011372

	Вох	No	o. I Basis of the opinion		
1.	With	With regard to the language, this opinion has been established on the basis of:			
		the	international application in the language in which it was filed		
		a ti pui	ranslation of the international application into , which is the language of a translation furnished for the rposes of international search (Rules 12.3(a) and 23.1 (b)).		
With regard to any nucleotide and/or amino acid sequence disclosed in the international necessary to the claimed invention, this opinion has been established on the basis of:			gard to any nucleotide and/or amino acid sequence disclosed in the international application and ary to the claimed invention, this opinion has been established on the basis of:		
	a. type of material:				
	[⊐	a sequence listing		
	[table(s) related to the sequence listing		
	b. format of material:				
	[on paper		
	[in electronic form		
	c. ti	me	of filing/furnishing:		
	{		contained in the international application as filed.		
	[filed together with the international application in electronic form.		
	ļ		furnished subsequently to this Authority for the purposes of search.		
3.		ha co	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto s been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.		
4.	Add	ditio	nal comments:		

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of				
	the entire international application			
\boxtimes	claims Nos. 1-27			
because:				
\boxtimes	the said international application, or the said claims Nos. 1-27 (industrial applicability) relate to the following subject matter which does not require an international search (specify):			
	see separate sheet			
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):			
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed (specify):			
	no international search report has been established for the whole application or for said claims Nos.			
	a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit:			
	furnish a sequence listing on paper complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it.			
	furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it.			
	pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13 ter.1(a) or (b).			
	a meaningful opinion could not be formed without the tables related to the sequence listings; the applicant did not, within the prescribed time limit, furnish such tables in electronic form complying with the technical requirements provided for in Annex C-bis of the Administrative Instructions, and such tables were not available to the International Searching Authority in a form and manner acceptable to it.			
	the tables related to the nucleotide and/or amino acid sequence listing, if in electronic form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.			
	See Supplemental Box for further details			

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-32

No: Claims

Inventive step (IS)

Yes: Claims

1-32

Claims No:

Industrial applicability (IA)

Yes: Claims

28-32

Claims

2. Citations and explanations

see separate sheet

Re Item III.

The subject-matter of claims 1-27 is related to subject-matter considered to be covered by the provisions of Rule 67.1 (iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4) (a) (l) PCT).

Re Item V.

Reference is made to the following documents:

- D1: WO 2005/104745 A (GLAXO GROUP LIMITED; LAINE, DRAMANE, I; PALOVICH, MICHAEL, R; MCCLELAN) 10 November 2005 (2005-11-10)
- D2: WO 2004/108076 A (SAMARITAN PHARMACEUTICALS; GEORGETOWN UNIVERSITY; PAPADOPOULOS, VASSIL) 16 December 2004 (2004-12-16)

1. Novelty

The subject-matter of claims 1-32 appears not to be disclosed in the prior art (Art. 33(2) PCT).

2. Inventive step

The subject-matter of claims 1-32 appears not to be obvious in the light of the prior art (Art. 33(3) PCT).